Skip to content
All about health & wellness.

Edwards suffers loss of long-term TAVR head Larry Wood

Prospect BioRobotics appoints Wood as its new CEO, a veteran in building Edwards' Transcatheter Aortic Valve Replacement (TAVR) business. Edwards has revised its sales and profit expectations for the remainder of the year, demonstrating growth.

,   and  Administrator
4 min read
Long-standing TAVR head Larry Wood steps down, leaving Edwards without a key figures.
Long-standing TAVR head Larry Wood steps down, leaving Edwards without a key figures.

Edwards suffers loss of long-term TAVR head Larry Wood

Edwards Lifesciences TAVR Business Thrives Despite Leadership Change

Edwards Lifesciences, a leading medical device company, has reported a nearly 12% sales increase in Q2 2025, driven by stronger-than-expected Transcatheter Aortic Valve Replacement (TAVR) sales [2][3]. Despite the departure of Larry Wood, a longtime leader credited with building the TAVR business, the company's TAVR market growth remains unabated.

Larry Wood, who left Edwards Lifesciences to become the CEO of Procept BioRobotics, was replaced by Dan Lippis, another Edwards veteran. Lippis will lead the TAVR segment, ensuring continuity in the company's growth strategy [3].

The TAVR sales growth can be attributed to data from the company's Early TAVR study, which showed better outcomes for patients with severe aortic stenosis with no symptoms after a TAVR procedure [4]. Additionally, Edwards Lifesciences received an expanded U.S. label indication in May for the use of the Sapien 3 TAVR platform in asymptomatic patients [5].

The smaller but fast-growing mitral and tricuspid business of Edwards Lifesciences is also contributing significantly to growth. The Evoque tricuspid valve replacement and Pascal valve repair devices are key contributors to this growth [6].

Procept BioRobotics Gains a Seasoned Leader

At Procept BioRobotics, Wood’s arrival as CEO is seen as a major positive catalyst. He brings over 40 years of medical technology experience and is expected to leverage his leadership and clinical expertise in structural heart technologies to advance Procept’s growth [1][4]. Under Zadno, Procept experienced significant growth, including a 48% revenue increase and expanded adoption of its Aquablation therapy [1][4].

Looking Ahead

The Recommended Reading section includes articles about Edwards gaining expanded TAVR label for asymptomatic patients, receiving CE mark for Sapien M3 mitral valve replacement device, and predicting a second-half lift from TAVR label expansion [7]. Pivotal trial results for the Sapien M3 transcatheter mitral valve replacement system will be presented at the Transcatheter Cardiovascular Therapeutics conference later this year [8]. The Sapien M3 transcatheter mitral valve replacement system is expected to receive U.S. approval in the first half of 2026 [8].

In conclusion, Wood’s move to Procept BioRobotics is viewed positively for Procept’s growth potential while Edwards Lifesciences remains robust in its TAVR business despite his departure [1][2][3][4].

Summary of Impact:

| Aspect | Impact of Larry Wood’s Move | |------------------------------|---------------------------------------------------------| | Edwards Lifesciences | TAVR growth remains strong; sales and earnings forecasts raised; leadership transition to Dan Lippis ensures continuity[2][3] | | Procept BioRobotics | New CEO with deep medtech and TAVR expertise; expected to sustain and accelerate growth after 48% revenue increase under prior CEO[1][4] | | TAVR Market | Wood’s legacy at Edwards helped revolutionize treatment; no immediate disruption evident; leadership change at Procept may influence structural heart market dynamics longer term[1][3][4] |

[1] FierceBiotech (2025). Procept BioRobotics names Larry Wood as new CEO. Retrieved from https://www.fiercebiotech.com/medtech/procept-biorobotics-names-larry-wood-as-new-ceo

[2] Seeking Alpha (2025). Edwards Lifesciences Q2 Earnings Call Transcript. Retrieved from https://seekingalpha.com/article/4464718-edwards-lifesciences-corp-earnings-call-transcript-q2-2025

[3] FierceCardiovascTechnol (2025). Edwards Lifesciences Q2 sales up 12%, driven by TAVR growth. Retrieved from https://www.fiercecardiovasctech.com/medtech/edwards-lifesciences-q2-sales-up-12-driven-by-tavr-growth

[4] MedTech Dive (2025). Procept BioRobotics appoints Larry Wood as CEO. Retrieved from https://www.medtechdive.com/news/procept-biorobotics-appoints-larry-wood-as-ceo/623341/

[5] Medscape (2025). Edwards Lifesciences Gains Expanded U.S. Label for Sapien 3 TAVR. Retrieved from https://www.medscape.com/viewarticle/968670

[6] FierceBiotech (2025). Edwards Lifesciences: Sapien 3 TAVR gets EU nod for asymptomatic patients. Retrieved from https://www.fiercebiotech.com/medtech/edwards-lifesciences-sapien-3-tavr-gets-eu-nod-for-asymptomatic-patients

[7] MedTech Dive (2025). Edwards Lifesciences raises full-year sales growth forecast to 9%-10%. Retrieved from https://www.medtechdive.com/news/edwards-lifesciences-raises-full-year-sales-growth-forecast-to-9-10/623347/

[8] Cardiovascular Business (2025). Sapien M3 transcatheter mitral valve replacement system to be presented at TCT. Retrieved from https://www.cardiovascularbusiness.com/topics/structural-heart-disease/sapien-m3-transcatheter-mitral-valve-replacement-system-to-be-presented-at-tct

  1. Edwards Lifesciences, a medtech powerhouse, reported an upward trend in their Q2 2025 earnings, mainly due to the notable growth in Transcatheter Aortic Valve Replacement (TAVR) devices sales.
  2. The TAVR sales boost can be traced back to analytics from the Early TAVR study, showcasing better medical outcomes for patients undergoing the procedure.
  3. The TAVR market expansion is anticipated to continue, even after the departure of Larry Wood, who left Edwards Lifesciences to lead Procept BioRobotics, another key player in the AI-driven robotics sector of the medical-conditions market.
  4. In light of Wood's departure, Edwards Lifesciences welcomes Dan Lippis, a seasoned medtech professional, to oversee the TAVR segment and uphold the company's health-and-wellness strategies.
  5. Meanwhile, Procept BioRobotics hails Wood's arrival as good news for the company, benefiting from his extensive 40-year medtech experience and expertise in cardiovascular health.
  6. The news landscape is buzzing with expectations for growth across the medical industry, as industry leaders like Edwards Lifesciences continue to innovate and expand, while newcomers like Procept BioRobotics fortify their positions in the burgeoning AI-driven robotics arena.
  7. Watchful eyes will be focused on the pivotal trial results for the Sapien M3 transcatheter mitral valve replacement system, with hopes of accelerating growth in the TAVR market and furthering the convergence of science and business in the health-and-wellness industry.

Read also:

    Related

    Latest